NCT03206255View on ClinicalTrials.gov

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

CompletedOBSERVATIONAL
Enrollment

940

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

August 15, 2018

Study Completion Date

August 15, 2018

Conditions
Cervical Intraepithelial NeoplasiaCervical CancerVaginal Intraepithelial NeoplasiaVulvar Intraepithelial NeoplasiaPersistent Infection
Interventions
PROCEDURE

3 doses of HPV 16/18 bivalent vaccine

Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)

PROCEDURE

2 doses of HPV 16/18 bivalent vaccine

Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)

Trial Locations (1)

210009

Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Jun Zhang

OTHER

NCT03206255 - Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls | Biotech Hunter | Biotech Hunter